In July 2016, the new Cancer Drugs Fund was launched. Since then, each year, Remap Consulting has been conducting an analysis of oncology appraisals conducted in England. This year, we focused our analysis on comparing market access for oncology and non-oncology drugs. Specifically, our research compared the outcomes of draft and final NICE outcomes and in the case of positive outcomes, the use of patient population restrictions and financial agreements for oncology and non-oncology drugs.
Read our findings here….(Oncology vs non-oncology drugs)